Abstract：【Objective】To investigate the efficacy of dendritic cell-cytokine-induced killer (DC-CIK) cell immunization combined with taxol plus carboplatin (TC) chemotherapy in patients with stage IIB-ⅣA cervical cancer. 【Methods】From September 2016 to August 2018, 72 patients with stage ⅡB-ⅣA cervical cancer in our hospital were selected and divided into observation group and control group with 36 cases in each group according to the random number table method. The control group was treated with TC chemotherapy, the observation group was treated with DC-CIK cell immunotherapy on the basis of the control group.Objective remission rate, disease control rate, Th1/Th2 secretion factor (IL-2, IL-10), PI3K / Akt signal transduction pathway index [phosphatidylinositol-3-kinase (PI3K), protein kinase B (Akt), amino terminal kinase 1 (JNK1)], osteopontin (OPN), endothelial glycoprotein (CD105) and the World Health Organization Quality of Life questionnaire summary score (WHOQOL-BREF) were compared between the two groups. 【Results】After 4 cycles of treatment, the objective remission rate and disease control rate of the observation group were 63.89% and 91.67%, respectively, which were significantly higher than 36.11% and 66.67% of the control group; IL-2 was higher than the control group, and IL-10 was lower than the control group; the levels of PI3K, Akt, JNK1, jnk2, JAK2, OPN and CD105 were lower than the control group, and the differences were statistically significant (P<0.05); the WHOQOL-BREF score of the observation group after 4 cycles of treatment was significant. It was higher than that of the control group (P<0.05).【Conclusion】DC-CIK cell immunity combined with TC chemotherapy in the treatment of ⅡB-ⅣA stage cervical cancer can inhibit tumor proliferation, invasion and metastasis, improve the immune function of patients, improve the quality of life of patients, and the effect is significant. The mechanism may be related to the inhibition of PI3K / Akt signal transduction pathway expression.
2019, Vol. 36 
